ATNFW Form 144: Proposed Sale of 189,959 Restricted Shares Valued $1.36M

Rhea-AI Filing Summary

Form 144 notice for 180 Life Sciences Corp. (symbol: ATNFW) discloses a proposed sale of 189,959 common shares, with an aggregate market value of $1,358,187.85. The shares were acquired as a restricted stock grant from the issuer on 02/20/2025 and the filer indicates an approximate sale date of 08/14/2025 through Oppenheimer & Co., Inc. The filing reports 6,039,208 shares outstanding and states there were no sales in the past three months by the filer. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Positive

• Full Rule 144 disclosure provided with acquisition date, grant type, broker, sale date, and aggregate value
• Seller attests to absence of undisclosed material adverse information, meeting regulatory representation requirements
• No sales in prior three months reported, clarifying recent disposition history

Negative

• Proposed sale size disclosed: 189,959 shares for $1,358,187.85 which may increase available float upon sale
• Restricted stock grant being sold indicates insider-origin shares entering market (transactional fact disclosed)

Insights

Financial Analyst

TL;DR Proposed sale of 189,959 restricted shares valued at $1.36M; routine insider disposition disclosure.

The filing shows a controlled, scheduled disposition of shares originally received as a restricted stock grant on 02/20/2025. The seller intends to transact via a broker (Oppenheimer) with an approximate sale date of 08/14/2025 and reports no other sales in the prior three months. This is a compliance-focused disclosure that notifies the market of potential share supply but contains no operational or financial performance details about the issuer.

Corporate Governance Expert

TL;DR Disclosure meets Rule 144 requirements; includes seller representation about material undisclosed information.

The notice provides the required details: acquisition date, nature of acquisition (restricted stock grant), number of shares, aggregate value, broker, and an affirmation that the seller lacks undisclosed material adverse information. It also confirms no reportable sales in the prior three months. The submission appears procedural and fulfills regulatory transparency obligations without revealing governance changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Oppenheimer & Co, Inc 85 Broad St New York NY 10004	189959	1358187.85	6039208	08/14/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/20/2025	restricted stock grant	issuer			189959	02/20/2025	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for 180 Life Sciences (ATNFW) disclose?

The filing discloses a proposed sale of 189,959 common shares valued at $1,358,187.85, intended to be sold on or about 08/14/2025 via Oppenheimer & Co.

When were the shares being sold acquired according to the Form 144?

The shares were acquired on 02/20/2025 as a restricted stock grant from the issuer.

How many shares outstanding does the filing report for 180 Life Sciences?

The filing reports 6,039,208 shares outstanding.

Did the filer report any sales in the prior three months?

The filer reported Nothing to Report for securities sold during the past three months.

Which broker is named in the Form 144 for the proposed sale?

The broker named is Oppenheimer & Co., Inc, located at 85 Broad St, New York, NY.